Product image of Myfortic (Mycophenolic Acid) supplied by GNH India

Myfortic

Active Ingredient:
Mycophenolic Acid
Origin:
EU

Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral delayed‑release tablet for systemic use. It is indicated for the prevention of organ rejection in kidney, heart and liver transplantation, helping to maintain graft function in adult recipients.

GNH India supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The product complies with EU regulatory standards and is manufactured under strict quality controls.

Manufacturer / TM Owner

Novartis Farma - Produtos Farmacêuticos S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myfortic is an antimetabolite immunosuppressant used in transplantation to inhibit lymphocyte proliferation.

  • Kidney transplantation: prevents acute and chronic rejection, supporting graft survival.
  • Heart transplantation: reduces incidence of rejection episodes, aiding long‑term cardiac graft function.
  • Liver transplantation: helps maintain liver graft tolerance and decreases rejection risk.

How It Works

  • Myfortic (mycophenolic acid) selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the enzyme responsible for de novo synthesis of guanosine nucleotides. By limiting guanosine availability, it suppresses proliferation of T‑ and B‑lymphocytes, which rely on this pathway for clonal expansion, thereby reducing immune responses that can lead to organ graft rejection.

Side Effects

Myfortic may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Gastrointestinal discomfort: nausea, vomiting, diarrhea, or abdominal pain.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.
  • Hematologic changes: anemia, leukopenia, or thrombocytopenia.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Severe infection: opportunistic or life‑threatening infections.
  • Progressive renal dysfunction: worsening kidney function.
  • Malignancy: increased risk of certain cancers.
  • Bone marrow failure: aplastic anemia or pancytopenia.

Precautions & Warnings

When prescribing Myfortic, clinicians should consider several safety precautions to minimize risks.

  • Monitor blood counts: perform regular complete blood count testing to detect cytopenias.
  • Assess renal function: adjust therapy based on creatinine clearance and monitor for nephrotoxicity.
  • Screen for infections: evaluate for active infections before initiation and during treatment.
  • Avoid pregnancy: discuss contraception as the drug may harm the fetus.
  • Drug interactions: review concomitant medications that affect IMPDH or increase infection risk.
  • Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Avoid Interactions

Myfortic can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Antimetabolites (e.g., azathioprine): additive immunosuppression may increase infection risk.
  • Live vaccines: heightened risk of vaccine‑derived infection.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce mycophenolic acid exposure.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may decrease absorption of mycophenolic acid.
  • ACE inhibitors or ARBs: combined use may affect renal function.
  • Cholesterol‑lowering agents (e.g., statins): monitor for increased mycophenolic acid levels.

Frequently Asked Questions

Myfortic is prescribed to prevent rejection of transplanted organs. It is approved for use in kidney, heart and liver transplantation, where it helps maintain graft function by suppressing the immune response that can damage the new organ.

Mycophenolic acid, the active component of Myfortic, blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition stops the synthesis of guanosine nucleotides, a building block needed for T‑ and B‑lymphocyte proliferation, thereby reducing the immune activity that leads to organ rejection.

The dose of Myfortic is individualized by the prescribing clinician based on factors such as the type of transplant, patient weight, renal function and concomitant immunosuppressive therapy. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for Myfortic in pregnancy and lactation are limited. Because the drug may pose a risk to the developing fetus, it is generally avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended without medical advice.

To request Myfortic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) belongs to the antimetabolite class, offering a different mechanism than calcineurin inhibitors such as tacrolimus or cyclosporine. Compared with azathioprine, Myfortic provides more selective inhibition of lymphocyte proliferation and is often preferred for its efficacy in preventing acute rejection, though individual regimens vary.

Myfortic tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Myfortic is taken orally as a delayed‑release tablet. It is usually swallowed whole with a glass of water, with or without food, as directed by the prescriber. The tablet should not be crushed, chewed, or split.

The most serious risks include severe or opportunistic infections, development of certain malignancies, and bone‑marrow suppression leading to conditions such as aplastic anemia or pancytopenia. Patients should be monitored closely for signs of infection, abnormal blood counts and any unexpected symptoms.

Myfortic should be avoided in individuals with known hypersensitivity to mycophenolic acid or any tablet excipients, in patients with uncontrolled active infections, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for patients with severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT